← Back to Search

Cancer Vaccine

Treatment (CMV-alphaDC1) for Cytomegalovirus

Phase 1

Waitlist Available

Led By George L Chen

Research Sponsored by Roswell Park Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a special vaccine to help patients who have had a specific medical procedure fight off a virus. The vaccine uses special cells to teach the immune system to recognize and attack the virus.

Eligible Conditions

Cytomegalovirus
Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Incidence of dose limiting toxicities

T-Lymphocyte

Secondary study objectives

Incidence of late CMV reactivation after allogeneic hematopoietic stem cell transplant

Perinatal death

Other study objectives

Incidence of adverse events

T-Lymphocyte

T-Cell Receptor

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (CMV-alphaDC1)Experimental Treatment3 Interventions

Patients undergo standard of care allogeneic hematopoietic stem cell transplant on day 0 and receive CMV-alphaDC1 vaccine intradermally on days 28, 42, 56, and 70.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biospecimen Collection

2004

Completed Phase 3

~2030

Allogeneic Hematopoietic Stem Cell Transplantation

2012

Completed Phase 2

~1240